NewAmsterdam Pharma (NAMS) said late Wednesday it has priced an underwritten public offering of 12.1 million shares at $24.50 per share and pre-funded warrants to purchase 4.9 million shares at $24.4999 per warrant.
The company said it has also granted underwriters a 30-day option to purchase up to 2.6 million additional shares
The company said it expects gross proceeds from the offering, anticipated to close on Thursday, of $416.5 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。